Traders Sell Pfizer Inc. (PFE) on Strength (PFE)
Traders sold shares of Pfizer Inc. (NYSE:PFE) on strength during trading on Wednesday. $55.04 million flowed into the stock on the tick-up and $102.66 million flowed out of the stock on the tick-down, for a money net flow of $47.62 million out of the stock. Of all equities tracked, Pfizer had the 8th highest net out-flow for the day. Pfizer traded up $0.05 for the day and closed at $35.13
Several research analysts recently commented on the company. Vetr upgraded Pfizer from a “hold” rating to a “buy” rating and set a $38.08 price target for the company in a research report on Tuesday, August 2nd. Sanford C. Bernstein set a $36.00 target price on Pfizer and gave the company a “buy” rating in a research report on Tuesday, May 3rd. Independent Research GmbH set a $37.00 target price on Pfizer and gave the company a “neutral” rating in a research report on Wednesday, May 4th. Leerink Swann dropped their target price on Pfizer from $37.00 to $34.70 and set a “market perform” rating for the company in a research report on Monday, May 2nd. Finally, Bank of America Corp. restated a “buy” rating and set a $28.25 target price (down previously from $38.48) on shares of Pfizer in a research report on Tuesday, May 10th. Ten investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Pfizer currently has an average rating of “Buy” and an average price target of $38.17.
The firm’s 50 day moving average price is $35.86 and its 200 day moving average price is $32.86. The company has a market cap of $213.06 billion and a PE ratio of 31.14.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.02. The business earned $13.10 billion during the quarter, compared to analysts’ expectations of $13.01 billion. The business’s quarterly revenue was up 10.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.56 EPS. On average, equities research analysts predict that Pfizer Inc. will post $2.46 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 1st. Shareholders of record on Friday, August 5th will be given a $0.30 dividend. The ex-dividend date is Wednesday, August 3rd. This represents a $1.20 annualized dividend and a yield of 3.42%.
In other Pfizer news, VP Loretta V. Cangialosi sold 86,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 24th. The shares were sold at an average price of $33.97, for a total value of $2,921,420.00. Following the completion of the transaction, the vice president now owns 271,663 shares of the company’s stock, valued at approximately $9,228,392.11. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Frank A. Damelio sold 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $34.49, for a total transaction of $3,449,000.00. Following the completion of the transaction, the executive vice president now directly owns 472,994 shares of the company’s stock, valued at approximately $16,313,563.06. The disclosure for this sale can be found here.
Other institutional investors have modified their holdings of the company. MetLife Securities Inc boosted its position in shares of Pfizer by 71.3% in the fourth quarter. MetLife Securities Inc now owns 221,106 shares of the biopharmaceutical company’s stock valued at $7,137,000 after buying an additional 92,009 shares in the last quarter. First Trust Advisors LP raised its stake in shares of Pfizer by 30.3% in the fourth quarter. First Trust Advisors LP now owns 2,797,198 shares of the biopharmaceutical company’s stock worth $90,294,000 after buying an additional 650,410 shares during the last quarter. Busey Trust CO raised its stake in shares of Pfizer by 1.5% in the fourth quarter. Busey Trust CO now owns 496,458 shares of the biopharmaceutical company’s stock worth $16,025,000 after buying an additional 7,124 shares during the last quarter. Smithfield Trust Co. raised its stake in shares of Pfizer by 2.4% in the fourth quarter. Smithfield Trust Co. now owns 75,268 shares of the biopharmaceutical company’s stock worth $2,429,000 after buying an additional 1,764 shares during the last quarter. Finally, Jackson Wealth Management LLC raised its stake in shares of Pfizer by 0.4% in the fourth quarter. Jackson Wealth Management LLC now owns 51,115 shares of the biopharmaceutical company’s stock worth $1,585,000 after buying an additional 214 shares during the last quarter.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.